268 related articles for article (PubMed ID: 28744974)
1. Obestatin regulates cardiovascular function and promotes cardioprotection through the nitric oxide pathway.
Penna C; Tullio F; Femminò S; Rocca C; Angelone T; Cerra MC; Gallo MP; Gesmundo I; Fanciulli A; Brizzi MF; Pagliaro P; Alloatti G; Granata R
J Cell Mol Med; 2017 Dec; 21(12):3670-3678. PubMed ID: 28744974
[TBL] [Abstract][Full Text] [Related]
2. Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes.
Alloatti G; Arnoletti E; Bassino E; Penna C; Perrelli MG; Ghé C; Muccioli G
Am J Physiol Heart Circ Physiol; 2010 Aug; 299(2):H470-81. PubMed ID: 20525876
[TBL] [Abstract][Full Text] [Related]
3. sGC-cGMP-PKG pathway stimulation protects the healthy but not the failing right ventricle of rats against ischemia and reperfusion injury.
Andersen A; Povlsen JA; Johnsen J; Jespersen NR; Bøtker HE; Nielsen-Kudsk JE
Int J Cardiol; 2016 Nov; 223():674-680. PubMed ID: 27568988
[TBL] [Abstract][Full Text] [Related]
4. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
Strande JL; Hsu A; Su J; Fu X; Gross GJ; Baker JE
Basic Res Cardiol; 2007 Jul; 102(4):350-8. PubMed ID: 17468933
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective PKG-independent NO signaling at reperfusion.
Cohen MV; Yang XM; Liu Y; Solenkova NV; Downey JM
Am J Physiol Heart Circ Physiol; 2010 Dec; 299(6):H2028-36. PubMed ID: 20852051
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways.
Hu Y; Chen X; Pan TT; Neo KL; Lee SW; Khin ES; Moore PK; Bian JS
Pflugers Arch; 2008 Jan; 455(4):607-16. PubMed ID: 17674030
[TBL] [Abstract][Full Text] [Related]
7. Treatment of rats with hypolipidemic compound pirinixic acid protects their hearts against ischemic injury: are mitochondrial K(ATP) channels and reactive oxygen species involved?
Nemčeková M; Čarnická S; Ferko M; Muráriková M; Ledvényiová V; Ravingerová T
Physiol Res; 2013; 62(5):577-84. PubMed ID: 24020817
[TBL] [Abstract][Full Text] [Related]
8. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-Kinase/Akt and NO pathway.
Bulhak AA; Jung C; Ostenson CG; Lundberg JO; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H719-27. PubMed ID: 19151258
[TBL] [Abstract][Full Text] [Related]
9. Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury.
Strande JL; Widlansky ME; Tsopanoglou NE; Su J; Wang J; Hsu A; Routhu KV; Baker JE
Cardiovasc Res; 2009 Jul; 83(2):325-34. PubMed ID: 19380418
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase.
Frankenreiter S; Groneberg D; Kuret A; Krieg T; Ruth P; Friebe A; Lukowski R
Cardiovasc Res; 2018 May; 114(6):822-829. PubMed ID: 29438488
[TBL] [Abstract][Full Text] [Related]
11. Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling.
Inserte J; Hernando V; Vilardosa Ú; Abad E; Poncelas-Nozal M; Garcia-Dorado D
J Am Heart Assoc; 2013 Jan; 2(1):e005975. PubMed ID: 23525447
[TBL] [Abstract][Full Text] [Related]
12. Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.
Perrelli MG; Tullio F; Angotti C; Cerra MC; Angelone T; Tota B; Alloatti G; Penna C; Pagliaro P
Pflugers Arch; 2013 Jul; 465(7):1031-40. PubMed ID: 23319164
[TBL] [Abstract][Full Text] [Related]
13. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
Ha T; Hu Y; Liu L; Lu C; McMullen JR; Kelley J; Kao RL; Williams DL; Gao X; Li C
Cardiovasc Res; 2010 Sep; 87(4):694-703. PubMed ID: 20421349
[TBL] [Abstract][Full Text] [Related]
14. Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning.
Lochner A; Marais E; Genade S; Huisamen B; du Toit EF; Moolman JA
Cardiovasc J Afr; 2009; 20(1):43-51. PubMed ID: 19287816
[TBL] [Abstract][Full Text] [Related]
15. The β subunit of soluble guanylyl cyclase GUCY1B3 exerts cardioprotective effects against ischemic injury via the PKCε/Akt pathway.
Wang X; Du W; Li M; Zhang Y; Li H; Sun K; Liu J; Dong P; Meng X; Yi W; Yang L; Zhao R; Hu J
J Cell Biochem; 2019 Mar; 120(3):3071-3081. PubMed ID: 30485489
[TBL] [Abstract][Full Text] [Related]
16. Promoting effect of baicalin on nitric oxide production in CMECs via activating the PI3K-AKT-eNOS pathway attenuates myocardial ischemia-reperfusion injury.
Bai J; Wang Q; Qi J; Yu H; Wang C; Wang X; Ren Y; Yang F
Phytomedicine; 2019 Oct; 63():153035. PubMed ID: 31377586
[TBL] [Abstract][Full Text] [Related]
17. Adenylyl cyclase-mediated effects contribute to increased Isoprenaline-induced cardiac contractility in TRPM4-deficient mice.
Uhl S; Mathar I; Vennekens R; Freichel M
J Mol Cell Cardiol; 2014 Sep; 74():307-17. PubMed ID: 24972051
[TBL] [Abstract][Full Text] [Related]
18. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.
Hamid SA; Bower HS; Baxter GF
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2598-606. PubMed ID: 17220176
[TBL] [Abstract][Full Text] [Related]
19. NDRG2: a newly identified mediator of insulin cardioprotection against myocardial ischemia-reperfusion injury.
Sun Z; Tong G; Ma N; Li J; Li X; Li S; Zhou J; Xiong L; Cao F; Yao L; Wang H; Shen L
Basic Res Cardiol; 2013 May; 108(3):341. PubMed ID: 23463182
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the nitric oxide/cyclic guanosine monophosphate pathway limited the cardioprotective effect of post-conditioning in hearts with apical myocardial infarction.
Correa F; Buelna-Chontal M; Chagoya V; García-Rivas G; Vigueras RM; Pedraza-Chaverri J; García-Niño WR; Hernández-Pando R; León-Contreras JC; Zazueta C
Eur J Pharmacol; 2015 Oct; 765():472-81. PubMed ID: 26387613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
